Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CASR | P41180 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.42 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.41 |
| ▸ | ESRRA | P11474 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6564631 | 0.88 | EPHX1 (0.47) | MCHR1HPGDMCHR2ESRRA | |
| SCHEMBL6567876 | 0.88 | RAF1 (0.44) | MCHR1MEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL6567969 | 0.88 | CASR (0.53) | MCHR1MEN1KMT2ACASR | |
| SCHEMBL6567939 | 0.88 | MCHR1 (0.53) | MCHR1MOK | |
| SCHEMBL6566675 | 0.87 | CASR (0.57) | MEN1LMNAKMT2ASMN1; SMN2CASR | |
| SCHEMBL6568066 | 0.87 | EPHX1 (0.49) | MEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL6566565 | 0.87 | PAX8 (0.55) | MCHR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6568064 | 0.86 | MCHR1 (0.46) | MCHR1ESRRA | |
| SCHEMBL6566738 | 0.86 | MCHR1 (0.45) | MCHR1MEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL6566645 | 0.85 | KDM4E (0.53) | MCHR1MEN1LMNAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | MCHR1 382/4885MEN1 4143/4885LMNA 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.